BACKGROUND: The primary objective of this phase 2 study was to assess the objective response rate (complete response [CR] + partial responses [PR]), by Response Evaluation Criteria in Solid Tumors, of PF-3512676, a CpG oligodeoxynucleotide, alone in 2 doses or in combination with dacarbazine (DTIC) in patients with unresectable stage IIIB/C or stage IV malignant melanoma, with the aim of selecting an arm to take forward to a phase 3 portion of the study. METHODS:A total of 184 patients were randomized to 1 of 4 treatments: PF-3512676 10 mg (low dose), at 40 mg (high dose), 40 mg plus DTIC (850 mg/m(2)), or DTIC (850 mg/m(2)) alone. Patients received PF-3512676 subcutaneously weekly in a 3-week cycle and received DTIC intravenously on the first week of the cycle. RESULTS: The objective response rate (PR or CR, confirmed or unconfirmed) in the 40 mg + DTIC arm was 16% (7 patients) compared with 8% (3 patients) with DTIC alone. One (2%) patient in the 10-mg and 0 patients in the 40-mg arms achieved an objective response. Best response of CR or PR or stable disease (SD), with no minimum duration defined for SD, was achieved by 15 (33%) patients in the 40 mg + DTIC arm, 15 (38%) patients in the DTIC-only arm, 8 (17%) patients in the 10-mg arm, and 9 (20%) patients in the 40-mg arm. The most frequently reported adverse events were classified as local injection site reactions or systemic flu-like symptoms, specifically fatigue, rigors, and pyrexia. CONCLUSIONS:PF-3512676 at the doses used was generally well tolerated. The modest objective response rates observed in all arms did not warrant continuation to the phase 3 portion of the study.
RCT Entities:
BACKGROUND: The primary objective of this phase 2 study was to assess the objective response rate (complete response [CR] + partial responses [PR]), by Response Evaluation Criteria in Solid Tumors, of PF-3512676, a CpG oligodeoxynucleotide, alone in 2 doses or in combination with dacarbazine (DTIC) in patients with unresectable stage IIIB/C or stage IV malignant melanoma, with the aim of selecting an arm to take forward to a phase 3 portion of the study. METHODS: A total of 184 patients were randomized to 1 of 4 treatments: PF-3512676 10 mg (low dose), at 40 mg (high dose), 40 mg plus DTIC (850 mg/m(2)), or DTIC (850 mg/m(2)) alone. Patients received PF-3512676 subcutaneously weekly in a 3-week cycle and received DTIC intravenously on the first week of the cycle. RESULTS: The objective response rate (PR or CR, confirmed or unconfirmed) in the 40 mg + DTIC arm was 16% (7 patients) compared with 8% (3 patients) with DTIC alone. One (2%) patient in the 10-mg and 0 patients in the 40-mg arms achieved an objective response. Best response of CR or PR or stable disease (SD), with no minimum duration defined for SD, was achieved by 15 (33%) patients in the 40 mg + DTIC arm, 15 (38%) patients in the DTIC-only arm, 8 (17%) patients in the 10-mg arm, and 9 (20%) patients in the 40-mg arm. The most frequently reported adverse events were classified as local injection site reactions or systemic flu-like symptoms, specifically fatigue, rigors, and pyrexia. CONCLUSIONS:PF-3512676 at the doses used was generally well tolerated. The modest objective response rates observed in all arms did not warrant continuation to the phase 3 portion of the study.
Authors: Julie K Jang; Leslie A Khawli; David C Canter; Peisheng Hu; Tian H Zhu; Brian W Wu; Trevor E Angell; Zhongjun Li; Alan L Epstein Journal: Cancer Immunol Immunother Date: 2016-03-09 Impact factor: 6.968
Authors: Yi Lin; Michael P Gustafson; Peggy A Bulur; Dennis A Gastineau; Thomas E Witzig; Allan B Dietz Journal: Blood Date: 2010-11-09 Impact factor: 22.113
Authors: Marcos Andre Rodrigues da Costa Santos; Jhenifer Santos Dos Reis; Carlos Antonio do Nascimento Santos; Kelli Monteiro da Costa; Pedro Marçal Barcelos; Karen Queiroz de Oliveira Francisco; Pedro Antônio Guimarães Notaroberto Barbosa; Emanuelle Damasceno Souza da Silva; Celio Geraldo Freire-de-Lima; Alexandre Morrot; Debora Decote-Ricardo; Israel Diniz-Lima; Jose Osvaldo Previato; Lucia Mendonca-Previato; Leonardo Marques da Fonseca; Leonardo Freire-de-Lima Journal: Immunol Res Date: 2022-10-05 Impact factor: 4.505
Authors: Haitao Fan; Ian Zhang; Xuebo Chen; Leying Zhang; Huaqing Wang; Anna Da Fonseca; Edwin R Manuel; Don J Diamond; Andrew Raubitschek; Behnam Badie Journal: Clin Cancer Res Date: 2012-08-17 Impact factor: 12.531
Authors: Alexander H Morrison; Mark S Diamond; Ceire A Hay; Katelyn T Byrne; Robert H Vonderheide Journal: Proc Natl Acad Sci U S A Date: 2020-03-25 Impact factor: 11.205